No Data
CytoMed Therapeutics Has Dosed The First Patient In Its First-In-Human Phase I Dose-Escalation ANGELICA Trial Of Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-Grafted Gamma Delta T Cells In Patients With Advanced Solid Tumors Or Hematological...
Osteopore Teams Up With CytoMed Therapeutics for Cellular Product Development; Shares Up 3%
CytoMed Therapeutics Price Target Maintained With a $5.00/Share by Benchmark
CytoMed Therapeutics Has Acquired The License And Certain Assets Of Cellsafe International, A Malaysian Cord Blood Bank, Deal Terms Were Not Disclosed
Earnings Preview: GDTC to Report Financial Results Pre-market on October 08
$CytoMed Therapeutics(GDTC.US)$ is scheduled to release its financial results pre-market on October 08 ET. Earnings PreviewAnalysts estimate $CytoMed Therapeutics(GDTC.US)$ to post revenue of SGD176.4
CytoMed Therapeutics Reports Interim Financial Loss
No Data
No Data